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Summary DT-diaphorase, a homodimericflavoenzyme, can provide for a defence mechanism againstcarcinogenesis mediated bydietary or
environmental quinones as well as bioactivate quinone-containing chemotherapeutic drugs. Human cell lines and strains have been identified
with very low or undetectable enzymatic activity and a C toTtransition at nucleotide 609 ofthe DT-diaphorase cDNA. Thissingle base change
is predicted to result in a proline to serine change in amino acid 187. Human cells homozygous for this base transition fail to exhibit Western
blot reactivity for DT-diaphorase, suggesting that this substitution results in protein instability. To directly testwhetherthis basechange affects
DT-diaphorase enzymatic activity and/or protein stability in vivo, mammalian expression vectors containing DT-diaphorase cDNA with or
without the nucleotide 609. base transition were transiently transfected in COS-1 cells. Co-transfection with a human growth hormone
expression vector allowed normalization fortransfection efficiency. COS-1 transfectants expressing the C to T base change displayed at least
a tenfold reduction in DT-diaphorase activity (P < 0.001) and a two- to threefold reduction in protein levels compared with wild-type
transfectants. These results are the first to detect the presence of DT-diaphorase protein coded for by the 609 base transition in mammalian
cells and confirm its predicted reduced enzymatic activity.
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DT-diaphorase [NAD(P)H (reduced nicotinamide adenine di-
nucleotide, with or without phosphate):quinone oxidoreductase
(NQO,), EC 1.6.99.2] is a homodimeric flavoprotein that acts on
its substrates by two-electron reduction (Ermster, 1967). It uses a
wide range of substrates, such as aromatic nitro and nitroso
compounds, phenolic antioxidants, azo dyes and quinone-
containing compounds (Horie, 1990; Ross et al, 1993). Reduction
of the quinone ring to its semiquinone radical form can be medi-
ated by one-electron reductases such as NADPH:cytochrome
P-450 reductase and NADH:cytochrome b5 reductase (Powis,
1987). However, DT-diaphorase converts the parent quinone to its
hydroquinone form in a single-step two-electron transfer reaction,
thereby by-passing semiquinone radical formation (Iyenagi,
1987). Redox cycling between the parent quinone and the semi-
quinone species in aerobic cells has been implicated in carcino-
genesis (Koster, 1991). Reduction of various dietary and
environmental quinones by DT-diaphorase may protect DNA and
cellular organelles against insults from reactive oxygen intermedi-
ates (Chesis et al, 1984; Powis, 1987; Lind et al, 1992).
Conversely, a number of quinone-containing chemotherapeutic
drugs such as mitomycin C, the indoloquinone E09, and the
aziridinylquinones can be activated by DT-diaphorase (Siegel et
al, 1990; Begleiter et al, 1992; Walton et al, 1992) into DNA
alkylating agents by conversion to their hydroquinone forms
in a single-step two-electron transfer reaction.
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In the BE human colon carcinoma cell line, a homozygous C to
T base transition in nucleotide 609 of DT-diaphorase cDNA has
been implicated in causing low to undetectable DT-diaphorase
activity (Traver et al, 1992). A wide range ofDT-diaphorase activ-
ities was observed in human fibroblast strains taken from a cancer-
prone family and unrelated donors (Marshall et al, 1991).
DT-diaphorase activity appeared to be related to the allelic status
at nucleotide 609 (C or T) in these cells, also suggesting that this
substitution may impair enzyme activity (Kuehl et al, 1995). In
addition, the BE cell line and human cell strains that have no or
very low DT-diaphorase activity have normal mRNA levels but
lack detectable levels of DT-diaphorase protein when tested
with polyclonal and/or monoclonal antibodies directed against
DT-diaphorase (Marshall et al, 1991; Traver et al, 1997). To test
the hypothesis that this base change impairs DT-diaphorase
enzymatic activity, mammalian expression vectors containing
DT-diaphorase cDNAs (derived from cells that are homozygous
for either the C or T nucleotide at position 609) were transiently
transfected into COS-1 monkey kidney cells that express very low
levels ofendogenous DT-diaphorase activity.
MATERIALS AND METHODS
Chemicals and reagents
2,6-Dichlorophenolindophenol (DCPIP), dicoumarol, FAD, bovine
serum albumin, [-NADPH, Tween-20 and Tris-HCl were obtained
from Sigma Chemical (St Louis, MO, USA). Lipofectamine
reagent was obtained from Life Technologies (Gibco-BRL,
Burlington, ON, Canada). Recombinant human growth hormone
levels in culture medium were determined using a commercially
available radioimmunoassay kit (Joldan Diagnostics, Aurora, ON,
Canada). Hybridoma supematants containing a mixture of two
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anti-DT-diaphorase monoclonal antibodies (B771, rat/human NQOI
reactive; A180 human NQO1 specific) as well as purified human
recombinant DT-diaphorase were supplied by Dr David Ross
(University ofColorado Health Sciences Center, Denver, CO, USA).
Preparation of eukaryotic expression vectors
Total RNA was isolated from the human fibroblast cell strains
GM38 and 3701T, which are homozygous for the C and T
nucleotide at position 609 respectively, as previously described
(Kuehl etal, 1995). Reverse transcriptase polymerase chain reaction
(RT-PCR) was used to amplify cDNAs using Superscript II reverse
transcriptase (Gibco) and AmpliTaq polymerase (Perkin Elmer,
Norwalk, CT, USA) corresponding to the DT-diaphorase open
reading frame using the following primers: 5'NQOI sense:
ATGCAAGCTAATCAGCGCCCCGGACTG (bases 23-40 of
NQO,; HindIII restriction site indicated by underline); 3'NQO1 anti-
sense: CGACGTCGACAAGGAAATCCAGGCTAAGGA (bases
879-898 ofNQO,; Sail site indicated by underline).
The resulting 895-bp fragments, containing the full-length DT-
diaphorase coding region, were inserted into the HindIH and Sail
sites ofp,3APr-l-neo (Kuehl, 1995). These constructs were digested
with HindlIl and XbaI to release DT-diaphorase cDNAs, which
were then gel-purified and subcloned into the pRc/CMV expression
vector (Invitrogen, San Diego, CA, USA). Constructs containing
DT-diaphorase cDNA inserts with a C or T nucleotide at position
609 were designated as pRc/CMV.DTD609c and pRc/CMV.DTD609T
respectively. Constructs were purified for transfection experiments
by two rounds of caesium chloride continuous density gradient
centrifugation. The sequence integrity of pRc/CMV.DTD609C and
pRc/CMV.DTD609T were verified by Sanger sequencing of both
strands using Sequence Version 2.0 T7 DNA polymerase (United
States Biochemical, Cleveland, OH, USA).
Cell culture
COS-1 monkey kidney cells were obtained from the American
Type Culture Collection (Rockville, MD, USA) and grown in
alpha minimum essential media supplemented with 10% fetal
bovine serum (Sigma Chemical, growth medium) and maintained
in a humidified atmosphere containing 5% carbon dioxide at
370C.
Transient transfection of NQO1 cDNA
COS-1 cells were seeded on 100-mm-diameter tissue culture
dishes (NUNC, Denmark) 24 h before transfection at a density of
90-100 cells mm-' in growth medium and maintained in ahumidi-
fied atmosphere with 5% carbon dioxide at 370C. Lipofectamine
transfection was performed according to the manufacturer's
protocol (Gibco-BRL). Briefly, transfections were performed
using 20gl (2 mg ml-') lipofectamine and 5 jig of
pRc/CMV.DTD609C or pRc/CMV.DTD609T co-transfected with 5 jg
of pXGH5 (Seldon et al, 1986) in 1.6 ml of antibiotic-free alpha
minimal essential media. Mock-transfected cells (Lipofectamine
only) and vector-control transfectants (pRc/CMV vector alone)
were similarly treated. Cells were incubated with this mixture for
5 h, followed by an overnight incubation with the addition of 10%
fetal bovine serum at which time the media were replaced with
fresh growth medium. Twenty-four hours later, an aliquot of
growth medium was retained for analysis of recombinant human
growth hormone levels and cells were harvested for recombinant
DT-diaphorase enzymatic assays.
Assay for DT-diaphorase enzymatic activity
Transfectants were harvested by scraping, centrifuged at 250g for
5 min at 4°C, resuspended in 1 ml of phosphate-buffered saline
(PBS), and lysed by exposure to five 10-s ultrasound pulses at
10-s intervals using a Vibra Cell sonicator (Sonics and Materials,
Danbury, CT, USA). DT-diaphorase activity, expressed as
nmol min-' mg-1 total protein, was determined according to a
modification (Kuehl et al, 1995) ofan assay developed by Benson
et al (1980) and is expressed as dicoumarol inhibitable activity
measured by the loss of DCPIP at 600 nm. DT-diaphorase
activities in cell extracts were determined in the presence of
35 ,UM DCPIP in a buffer containing 25 mM Tris-HCl (pH 7.4),
0.23 mg ml-1 bovine serum albumin, 0.2 mm NADPH, 0.01%
Tween-20, 4gM flavin adenine dinucleotide, with orwithout 25 tM
dicoumarol. Protein concentration was measured using the
Bradford method (1976).
Western blot analysis
COS-1 cells were transfected with DT-diaphorase expression
vectors, grown to a density of 4 x 105 cells in 100-mm-diameter
tissue culture dishes and harvested by scraping in 2 ml of PBS.
Half the cell suspension was used to determine DT-diaphorase
activity as described above, whereas the remaining half was used
for Western blot analysis (Bumette, 1981). Cell lysates were
prepared by resuspending cell pellets in 200 1l-l cell harvest
buffer [0.1 M Tris-HCl, 1% sodium dodecyl sulphate (SDS),
10 mM EDTA, 20 nim dithiothreitol (DTT)] and incubation in a
boiling water bath for 2 min. Protein concentration was measured
using the Bradford method (1976) and protein (20 jg per lane)
was separated by 12% SDS polyacrylamide gel electrophoresis
and electrotransferred to nitrocellulose membranes. After transfer,
membranes were blocked in Tris-buffered saline containing 5%
skim milk powder and 1% heat-inactivated fetal bovine serum for
2 h, and then incubated overnight with 15 ml ofhybridoma super-
natant containing a mixture of two of the anti-DT-diaphorase
monoclonal antibodies at 4°C. Blots were washed in Tris-buffered
saline containing 0.05% Tween-20 and incubated for 90 min with
a 1:4000dilution ofgoatanti-mousehorseradish peroxidase conju-
gated antibody in Tris-buffered saline containing 1% skim milk
powder and 1% heat-inactivated fetal bovine serum. Bands were
visualized using an enhanced chemiluminesense detection kit
(Amersham Life Science, Oakville ON, Canada) and autoradiog-
raphy. Purified human recombinant DT-diaphorase (20 ng) was
included as a positive molecular weight control. Densitometric
analysis was performed using a Computing Densitometer and
ImageQuant v. 3.3 software package (Molecular Dynamics,
Sunnyvale, CA, USA). Band densities were quantified in ng rela-
tive to apositive molecular weight control.
Statistical analysis
DT-diaphorase activity was expressed as nmol/min/mg protein/ng
human growth hormone. Two-way analysis ofvariance (ANOVA)
was used to compare the means of enzymatic activities in
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COS-l cells transfected with either pRc/CMV.DTD609c or
pRc/CMV.DTD609T. Data were evaluated as two treatments
(pRc/CMV.DTD6C or pRc/CMV.DTD"T), each was represented
by three separate experiments. Two-way ANOVA allows compar-
ison of means of treatments by separating the intraexperimental
variation from interexperimental variation.
RESULTS
Co-transfection of COS-1 cells
COS-l cells were transiently transfected with eukaryotic expres-
sion vectors containing DT-diaphorase cDNAs prepared from
mRNA extracted from GM38 or 3701T skin fibroblast strains,
which are homozygous for either the C or T nucleotide at position
609 respectively (Kuehl et al, 1995). Untransfected COS-1 cells
displayed abackground activity within the limit ofdetection ofthe
assay, as did mock-transfected and vector-control transfected cells
(mean ± s.d. of three determinations 3.6 ± 2.2, 3.3 ± 2.2 and
2.0 ± 0.6 nmol min-' mg-' protein respectively). DT-diaphorase
activities of pRc/CMV.DTD6wc and pRc/CMV.DTD609T transfec-
tants were corrected for average background enzymatic activity.
Two-way ANOVA indicated that DT-diaphorase activities in cells
transfected with pRc/CMV.DTD609c or pRc/CMV.DTD609T were
significantly different (P <<0.001).
To control for the possibility that differences in DT-diaphorase
activities arise from differences in transfection efficiencies, cells
were simultaneously transfected with the pXGH5 plasmid, which
provides forrecombinant human growthhormone expression from
the mouse metallothionein-I promotor. Two-way ANOVA indi-
cated that recombinant human growth hormone levels were similar
in both pRc/CMV.DTD6wc and pRc/CMV.DTD609T co-transfec-
tants for each experiment (P>>0.1).
DT-diaphorase activities were normalized to recombinant
human growth hormone levels (transfection efficiency) and two-
way ANOVA confirmed the significant difference in DT-
diaphorase activities inpRc/CMV.DTD609C and pRc/CMV.DTD609T
transfectants (P<<0.001) (Figure 1). COS-1 cells transfected with
pRc/CMV.DTD6wc displayed mean DT-diaphorase activities of
260 ± 110 nmol min-' mg-' protein ng-' hGH, which were tenfold
greater than activities observed in pRc/CMV.DTD609T transfectants
(25 ± 15 nmol min-m mg-' protein ng-' hGH). These results
confirmed that DT-diaphorase cDNAs containing a T nucleotide
at position 609 encode a DT-diaphorase protein with reduced
enzymatic activity.
Western blot analysis
To examine whether the C to T nucleotide substitution leads to
decreased protein stability, recombinant DT-diaphorase protein
levels were also examined in COS-1 cells transfected with either
the pRc/CMV.DTD609C or pRc/CMV.DTD69T constructs. As
shown in Figure 2A, Western blot analysis of two independent
pRc/CMV.DTD609C or pRc/CMV.DTD609T transfected cell extracts
demonstrated that both mutant and wild-type recombinant DT-
diaphorase are expressed athigh levels in COS-I cells. The mutant
DT-diaphorase protein appeared to run slightly faster than the
wild-type DT-diaphorase protein and densitometry (Figure 2B)
indicated that wild-type transfectants contained approximately
threefold greater DT-diaphorase protein than mutant transfectants
(mean amounts of DT-diaphorase protein loaded from wild-type
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Figure 1 Mean DT-diaphorase activities in COS cells transfected with
plasmid constructs pRc/CMV.DTDww or pRc/CMV.DTD6wT. DT-diaphorase
activities are normalized for transfected efficiencies and are expressed as
nmol min-' mg-' protein ng-1 hGH. Values represent the means ± s.d. of three
independent expenments. *, 609C normalized DTD activity; rO, 609T
normalized DTD activity
and mutant extracts were estimated to be 240 and 80 ng respec-
tively). These results suggest that lower mutant DT-diaphorase
enzyme activities cannot beentirely accounted forby adecrease in
protein stabilities.
DISCUSSION
DT-diaphorase has been shown to reduce quinone-containing
chemotherapeutic drugs such as mitomycin C and the indolo-
quinone E09 to their hydroquinone forms leading to the forma-
tion of DNA-alkylating agents (Verwiej et al, 1994; Workman,
1994). These drugs may be used to target tumour cells that are
rich in DT-diaphorase. Elevated DT-diaphorase activity has been
observed in a number oftumour cell lines (Robertson et al, 1992).
Tumour biopsy material from patient lung, colon and breast have
also been shown to contain elevated DT-diaphorase activities
compared with surrounding normal tissue (Koudstaal et al, 1975;
Schlager et al, 1990).
The actual role of DT-diaphorase in controlling cell sensitivity
to quinone-containing drugs is, however, controversial as one-
electron reductases may also play important roles, especially in
hypoxic cells (Rauth et al, 1993; Rockwell et al, 1993). The recent
work of Fitzsimmons et al (1996) showing a correlation between
DT-diaphorase enzymatic activity and aerobic sensitivity to mito-
mycin C and E09 in the National Cancer Institute human tumour
cell line panel is currently the best evidence for this role. The one-
electron reductases NADPH:cytochrome P-450 reductase and
NADH:cytochrome b5 reductase fail to display such a correlation
in this study. The alternative role for DT-diaphorase as a detoxi-
fying agent, by one-step two-electron reduction of dietary and
environmental quinones to redox active products remains a poten-
tially important function for the enzyme (Powis, 1987).
Cells that are homozygous for a C to T nucleotide transition
at position 609 of the DT-diaphorase cDNA were found to
contain low to undetectable DT-diaphorase enzymatic activities
British Journal ofCancer (1998) 77(8), 1236-1240
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Figure 2 (A) Western blot analysis of cell lysates of COS-1 cells
transfected with pRc/CMV.DTD609 (6090), pRc/CMV.DTD609T (609T),
pRc/CMV vector alone, and untransfected controls (Untrans). Blots were
incubated with a mixture of DT-diaphorase monoclonal antibodies as
described in Materials and methods and processed using an ECL detection
kit and autoradiography. Purified human recombinant DT-diaphorase (20 ng)
was included as a positive molecular weight control (rTD). (B) Densitometry
analysis of DT-diaphorase band intensities. Values represent means ± s.d. of
five densitometric readings for each lane standardized to the purified
recombinant DT-diaphorase positive molecular weight control (rDTD)
(Traver et al, 1992). It is estimated that approximately 40% of
individuals are heterozygous for this nucleotide transition,
whereas 10% are homozygous (KuehI et al, 1995). Limited data
have shown that this point mutation is widespread (Rosvold et al,
1995; Rothman et al, 1996), occurs in both normal tissues and
tumours ofthe same individual (Eickelmann et al, 1994; Traver et
al, 1997) and may occur with altered frequencies in different
ethnic groups (Rothman et al, 1996).
Observations of human cells that are homozygous for the DT-
diaphorase nucleotide 609 point mutation and do not express
detectable DT-diaphorase protein (Marshall et al, 1991; Kuehl et
al, 1995; Traver et al, 1997) raised the possibility that this muta-
tion leads to destabilization of the protein product. The results in
Figure 2 indicate that there is a threefold reduction of mutant rela-
tive to wild-type protein in transfected COS-lI cells. Repeats of
this experiment have given values ranging from two- to threefold
reduction. Traver et al (1997) have reported that that purified
recombinant serine 187 mutant DT-diaphorase expressed in
Escherichia coli exhibits 2% specific enzymatic activity of wild-
type protein. Wu et al (1997) have similarly expressed the mutant
isoform in E. ccli and have shown that relative to wild-type protein
it has 3-4% specific activity with DCPIP as substrate. In addition
to measuring catalytic properties, they found that the dissociation
constant for FAD ofthe mutant isoform was twenty times the wild-
type enzyme and suggested that the point mutation changes
enzyme conformation.
Decreased mutant DT-diaphorase protein stability has also been
reported by Pan et al (1995) in studies of an arginine to tryptophan
139 substituted isoform in the HCT 116-R30A human colon
cancer cell subline, which is resistant to mitomycin C and
hooygu frtepIntmtto noigtisfr.Ti
mutant DT-diaphorase protein was detected by Western blot
analysis in HCT 116-R30A cells, but at 5% of the levels present
in the parental mitomycin C-sensitive line. This mutant isoform
was also expressed at detectable levels in E. coli and COS-7 cells
(Hu et al, 1996). Therefore, stable expression of this DT-
diaphorase isoform may be cell-type specific. However, as the
tryptophan 139 mutant has enzymatic activity similar to the wild-
type enzyme, the reduced activity displayed by HCT 116-R30A
cells has been attributed to the low levels of mutant DT-
diaphorase protein. The present paper suggests that the serine 187
mutation results in a reduction in both enzymatic activity and
protein stability. Therefore, cells that express the serine 187
mutant would be predicted to be resistant to drugs targeted for
DT-diaphorase activation.
The proline to serine substitution at amino acid 187 in DT-
diaphorase may predispose individuals to cancer by removing an
enzymatic defence mechanism against carcinogenesis. However,
the importance ofDT-diaphorase in cancer prevention is not clear,
and factors such as the interplay of DT-diaphorase with other
enzymes acting on common substrates need to be investigated
further. The results of this study provide further support for a
causal link between the C to T mutation at nucleotide 609 and
predisposition to cancer. This mutation may also serve as a prog-
nostic indicator for the effectiveness of chemotherapeutic drugs
activated by this enzyme.
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